Contribution of Medicine Taking on Treatment Burden in CKD patients
Research type
Research Study
Full title
The Contribution of Polypharmacy and Medicine Adherence to Treatment Burden and health-related Quality of Life among people with chronic kidney disease that is not dialysis or transplant-dependent
IRAS ID
320214
Contact name
Paul Rutter
Contact email
Sponsor organisation
UNIVERSITY OF PORTSMOUTH
Clinicaltrials.gov Identifier
MN/IND, University of Portsmouth
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Background
Chronic kidney disease (CKD) affects around 30% of the elderly population in the United Kingdom and often coexists with other long-term medical conditions. Any long-term condition provides challenges to the person for example the need to arrange and keep doctor's appointments, undergo medical testing, and take prescribed medicines. This workload and its impact is described as “Treatment burden” and refers to the additional and continuing obligations that patients must undertake in order to manage their health conditions.’ Taking medicines to treat long-term conditions is the commonest form of medical intervention and many patients need to take multiple medicines – this is called 'Polypharmacy'. However, little is known about how much of a toll this may have on patients' lives, especially in those patients with CKD.Aims
This study aims to explore treatment burden associated with medicine taking in people with non dialysis or transplant-dependent CKD.Methods
Participants will take part in an in-person, telephone or online interview that will last between 30 and 60 minutes.
The purpose of these interviews is to learn more about experiences with managing their health and to understand the factors that influence whether medicine taking leads to treatment burden.REC name
North East - York Research Ethics Committee
REC reference
24/NE/0104
Date of REC Opinion
27 Jun 2024
REC opinion
Further Information Favourable Opinion